Abstract
The US Food and Drug Administration has approved a diverse group of effective osteoporosis therapies. However, these therapies obviously only work when patients with osteoporosis take them. Data from retrospective observational databases have shown poor compliance and persistence with all osteoporosis drugs, particularly oral bisphosphonate therapy. Patients on weekly therapies are more compliant and persistent than those on daily dosing. Data have also shown decreased fracture risk, decreased health care utilization, and lower costs in compliant and persistent patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
World Health Organization: Adherence to long-term therapies: evidence for action. Available at http://www.emro.who.int/ncd/Publications/adherence_report.pdf. Accessed February 8, 2008.
Cramer JA, Roy A, Burrell A, et al.: Medication compliance and persistence: terminology and definitions. Available at http://www.ispor.org/sigs/medcompliance/medicationcomplianceandpersistence.asp. Accessed February 8, 2008.
Recker RR, Gallagher R, MacCosbe PE: Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005, 80:856–861.
Sunyecz J, Gallagher R, MacCosbe P: Persistence with medication in women taking daily versus weekly bisphosphonates for osteoporosis. Female Patient 2006, 31:21–28.
Ettinger M, Gallagher R, MacCosbe P: Medication persistence with weekly vs. daily doses of oral bisphosphonates. Endocr Pract 2006, 12:522–528.
Cramer JA, Amonkar MM, Hebborn A, Altman R: Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005, 21:1453–1460.
Brankin E, Walker M, Lynch N, et al.: The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin 2006, 22:1249–1258.
Cramer JA, Lynch NO, Gaudin AF, et al.: The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 2006, 28:1686–1694.
Silverman SL, Cramer JA, Sunyecz JA, et al.: Women are more persistent with monthly bisphosphonate therapy compared to weekly bisphosphonates: 12-month results from two retrospective databases [abstract W366]. Presented at the 29th Annual Meeting of the American Society for Bone and Mineral Research. Honolulu, HI; September 16–20, 2007.
Cooper A, Drake J, Brankin E; the PERSIST Investigators: Treatment persistence with once monthly ibandronate and patient support vs once weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006, 60:896–905.
Gold DT, Safi W, Trinh H: Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 2006, 22:2383–2391.
Weiss TW, Henderson SC, McHorney CA, Cramer JA: Persistence across weekly and monthly bisphosphonates: analysis of US retail prescription pharmacy refills. Curr Med Res Opin 2007, 23:2193–2203.
Cramer JA, Silverman SL, Gold DT: Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis. Curr Med Res Opin 2007, 23:2369–2377.
Curtis JR, Westfall A, Cheng H, et al.: Longitudinal patterns of adherence with bisphosphonates. Presented at the 29th Annual Meeting of the American Society for Bone and Mineral Research. Honolulu, HI; September 16–20, 2007.
Curtis JR, Westfall A, Allison JJ, et al.: Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos Int 2006, 17:1268–1274.
Yood RA, Emani S, Reed JI, et al.: Compliance with pharmacologic therapy for osteoporosis. Osteoporosis Int 2003, 14:965–968.
Silverman SL, Gold DT, Cramer JA: Reduced fracture rates observed only in patients with proper persistence and compliance with bisphosphonate therapies. South Med J 2007, 100:1214–1218.
Siris ES, Harris ST, Rosen CJ, et al.: Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures using 2 US claims databases. Mayo Clin Proc 2006, 81:1013–1022. [Comment in: Mayo Clin Proc 2006, 81:1009–1012.]
Caro JJ, Ishak KJ, Huybrechts KF, et al.: The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004, 15:1003–1008.
Weycker D, Macarios D, Edelsberg J, Oster G: Compliance with osteoporosis drug therapy and risk fracture. Osteoporos Int 2007, 18:271–277.
Kamatari M, Koto S, Ozawa N, et al.: Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab 2007, 25:302–309.
Badamgarav E, Fitzpatrick LA: A new look at osteoporosis outcomes: the influence of treatment, compliance, persistence, and adherence. Mayo Clin Proc 2006, 81:1009–1012.
McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J: Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004, 48:271–287.
Gold DT, Martin BC, Frytak JR, et al.: A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin 2007, 23:585–594.
Cramer JA, Gold DT, Silverman, SL, Lewiecki EM: A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007, 18:1023–1031.
de Klerk E, van der Heijde D, Landewe R, et al.: Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003, 30:44–54. [Erratum in: J Rheumatol 2003, 30:423.]
Dominick KL, Golightly YM, Bosworth HB: Racial differences in analgesic/anti-inflammatory medication adherence among patients with osteoarthritis. Ethn Dis 2005, 15:116–122.
Nived O, Andersson M, Lindgren M, et al.: Adherence with advice and prescriptions in SLE is mostly good, but better follow up is needed: a study with a questionnaire. Lupus 2007, 16:701–706.
Eastell R: Management of bone health in postmenopausal women. Horm Res 2005, 64(Suppl 2):76–80.
Lewiecki M: Medications don’t work if patients don’t take them [editorial]. South Med J 2007, 100:1190–1191.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Silverman, S.L., Gold, D.T. Compliance and persistence with osteoporosis therapies. Curr Rheumatol Rep 10, 118–122 (2008). https://doi.org/10.1007/s11926-008-0021-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11926-008-0021-x